Cellectar Biosciences, Inc. financial data

Symbol
CLRB on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Campus Drive, Florham Park, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
NOVELOS THERAPEUTICS, INC. (to 2/11/2014), COMMON HORIZONS INC (to 6/2/2005)
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 176 % +181%
Debt-to-equity 138 %
Return On Equity -328 % -196%
Return On Assets -132 % +57.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.1M shares +42.8%
Common Stock, Shares, Outstanding 46.1M shares +122%
Entity Public Float 89.1M USD +371%
Common Stock, Value, Issued 461 USD +123%
Weighted Average Number of Shares Outstanding, Basic 36.6M shares +200%
Weighted Average Number of Shares Outstanding, Diluted 37.1M shares +204%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.1M USD -4.14%
General and Administrative Expense 25.6M USD +119%
Costs and Expenses 51.8M USD +32.9%
Operating Income (Loss) -51.8M USD -32.9%
Nonoperating Income (Expense) 7.26M USD +127%
Net Income (Loss) Attributable to Parent -44.6M USD -4.23%
Earnings Per Share, Basic -1.22 USD/shares +65.1%
Earnings Per Share, Diluted -1.4 USD/shares +60%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.3M USD +143%
Assets, Current 24.3M USD +132%
Property, Plant and Equipment, Net 757K USD -30.6%
Operating Lease, Right-of-Use Asset 437K USD -13%
Other Assets, Noncurrent 29.8K USD 0%
Assets 25.5M USD +111%
Accounts Payable, Current 4.11M USD -27%
Liabilities, Current 9.39M USD -63%
Operating Lease, Liability, Noncurrent 410K USD -17.1%
Liabilities 9.8M USD -62.1%
Retained Earnings (Accumulated Deficit) -247M USD -22%
Stockholders' Equity Attributable to Parent 14.3M USD
Liabilities and Equity 25.5M USD +111%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.4M USD -86%
Net Cash Provided by (Used in) Financing Activities 43.8M USD
Net Cash Provided by (Used in) Investing Activities -21.6K USD
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 46.1M shares +122%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 30.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.3M USD +143%
Deferred Tax Assets, Valuation Allowance 107M USD +22.3%
Deferred Tax Assets, Gross 108M USD +22.2%
Operating Lease, Liability 494K USD -10.7%
Payments to Acquire Property, Plant, and Equipment 21.6K USD
Lessee, Operating Lease, Liability, to be Paid 657K USD -16.7%
Property, Plant and Equipment, Gross 1.98M USD +77.8%
Operating Lease, Liability, Current 84.4K USD +43.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 150K USD +2.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 146K USD +10.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 163K USD -30.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 153K USD +2%
Preferred Stock, Shares Issued 111 shares 0%
Preferred Stock, Shares Authorized 1.23K shares -82.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 155K USD +1.31%
Additional Paid in Capital 261M USD +42.7%
Preferred Stock, Shares Outstanding 111 shares 0%
Depreciation, Depletion and Amortization 88.5K USD +108%
Deferred Tax Assets, Net of Valuation Allowance 107M USD +22.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%